On 26 October, European laser technology group Lumibird reported revenue for the first nine months of 2026: consolidated €168.8 million, up 8.8% (+10.3% like-for-like), with third-quarter revenue of €54.1 million, up 12.0%. The Photonics division reached €86.8 million, up 13.5%, including photonic medtech at €16.6 million, up 75.9% (Q3 alone +117.2%), and Defence & Space at €41.8 million, up 10.3%. The Medical division grew 4.3% to €82.0 million, recovering to +14.4% in Q3. The company expects a record fourth quarter and confirmed the Medical division sale will complete by 31 December 2026 at the latest.
01 / Headline: €168.8M, with Q3 accelerating
Consolidated revenue for the first nine months was €168.8 million, up 8.8% (+10.3% like-for-like), split €49.7M in Q1, €65.0M in Q2 and €54.1M in Q3, with Q3 up 12.0% year on year. By division: Photonics €86.8 million (+13.5%, +14.9% like-for-like) and Medical €82.0 million (+4.3%, +5.8% like-for-like).
Photonics by region: EMEA €49.9 million (+7.7%), the Americas €21.2 million (+38.8%), Asia-Pacific €9.6 million (+26.1%) and the rest of the world €6.2 million (−15.9%). The Americas and Asia-Pacific growth was driven mainly by photonic medtech and Industrial & Scientific; EMEA leaned on Defence & Space.
02 / Structure: medtech and defence drive, industrial flat
The Photonics split carries the most signal: Defence & Space €41.8 million (+10.3%), though Q3 alone fell 2.0% — the company cites last year’s +42.9% base and deliveries postponed to Q4, with the order book still supporting growth. Photonic medtech reached €16.6 million (+75.9%), with Q3 alone up 117.2%, driven by new cardiovascular programmes. Industrial & Scientific was flat at €20.9 million (+0.6%), held up by flat-panel display repair, quantum technologies and semiconductor diagnostics, with Q3 down 9.0% again on a high base. Environment, Topography & Security fell 10.3% to €7.5 million but returned to +5.9% growth in Q3, with lidar-related commercial initiatives continuing.
The Medical division grew 4.3% to €82.0 million, with Q3 at €26.4 million (+14.4%): strong direct operations in the United States and Japan, a recovering European distribution market, and new glaucoma and retina product launches in Q3. Diagnostics were 24% of the division’s revenue and treatment solutions 76%.
03 / Outlook and limits: a sale pending, a record Q4 promised
Two forward items are worth noting. First, the Medical division sale announced in September 2026 should complete by 31 December 2026 at the latest (subject to the usual conditions precedent) — after which Lumibird becomes a pure photonics company, and its future reports will read quite differently. Second, the company expects a record fourth quarter for both the Photonics division and the Group, underpinned by the ramp-up of Defence & Space and medtech programmes and the Medical division’s continued recovery.
The limits deserve equal ink: this disclosure is unaudited; the Q3 declines in Defence & Space and Industrial & Scientific both carry high-base and delivery-timing explanations, so the promised “record” Q4 depends on deferred deliveries landing on schedule; and chairman and CEO Marc Le Flohic’s remarks on “expertise in critical technologies and components” and technological sovereignty are the company’s own wording. Full-year 2026 revenue follows on 25 January 2027 after close of trading, when Q4’s quality can be checked.
PRIMARY REFERENCES & LINKS
- Lumibird: Photonics continues its strong growth with a +13.5% increase in revenue over the first 9 months of 2026
Official press release read in full; used to verify all figures, divisional splits and the timeline. Figures are unaudited; vendor claims were not independently verified.
Open source link ↗ - Lumibird: Sustained Growth in Photonics
Third-party release summary; used to cross-check the headline totals and the Photonics growth rate.
Open source link ↗
